Jazz Pharmaceuticals plc has received FDA approval for Modeyso, a treatment for rare pediatric brain tumors. The drug showed a 22% overall response rate in clinical trials, with a median response duration of 10.3 months. The company is also expanding its pipeline with new therapies in neuroscience and oncology.

While Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is making strides in the healthcare sector with new treatments, some may find greater investment potential in AI stocks. For those interested in undervalued AI stocks with promising growth potential, a free report on the best short-term AI stock is available.

For more insights on potential investment opportunities, consider exploring articles on 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. No disclosures were made in this article.

Read more at Yahoo Finance: Jazz Pharmaceuticals plc (JAZZ) Wins FDA Nod for Modeyso in Rare Pediatric Brain Tumors